#HSE #HealthServiceExecutive #Ireland #hidradenitissuppurativa #HS #axialspondyloarthritis #axSpA #Bimekizumab #BIMZELEX #NadegeFeeser #Immunology #UCB #chronicdiseases #BrianKirby #Dermatology #HSpatients #phase3studies #clinicaltrial #BEHEARD1 #BEHEARD2 #moderatetosevereHS
zurl.co/NrDNa
zurl.co/NrDNa
HSE approves new treatment for hidradenitis suppurativa and axial spondyloarthritis - PharmaTimes
Bimekizumab offers fresh option for patients with chronic conditions
pharmatimes.com
December 1, 2025 at 11:07 AM